Literature DB >> 23845832

A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT & SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320: in regard to Sperduto et al.

H Ian Robins, Anne O'Neill, Minesh Mehta, Stuart Grossman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23845832      PMCID： PMC4086629          DOI： 10.1016/j.ijrobp.2013.03.040

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN： 0360-3016            Impact factor:   7.038


× No keyword cloud information.
  3 in total

1.  Whole-brain radiation therapy plus concomitant temozolomide for the treatment of brain metastases from non-small-cell lung cancer: a randomized, open-label phase II study.

Authors:  Daniel Chua; Maciej Krzakowski; Christos Chouaid; Maria G Pallotta; Jose I Martinez; Maya Gottfried; Walter Curran; Nikolaos Throuvalas
Journal:  Clin Lung Cancer       Date:  2010-05       Impact factor: 4.785

2.  Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases.

Authors:  D Antonadou; M Paraskevaidis; G Sarris; N Coliarakis; I Economou; P Karageorgis; N Throuvalas
Journal:  J Clin Oncol       Date:  2002-09-01       Impact factor: 44.544

3.  A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320.

Authors:  Paul W Sperduto; Meihua Wang; H Ian Robins; Michael C Schell; Maria Werner-Wasik; Ritsuko Komaki; Luis Souhami; Mark K Buyyounouski; Deepak Khuntia; William Demas; Sunjay A Shah; Lucien A Nedzi; Gad Perry; John H Suh; Minesh P Mehta
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-02-04       Impact factor: 7.038
  3 in total
  4 in total

1.  RADVAN: a randomised phase 2 trial of WBRT plus vandetanib for melanoma brain metastases - results and lessons learnt.

Authors:  Avinash Gupta; Corran Roberts; Finn Tysoe; Matthew Goff; Jenny Nobes; James Lester; Ernie Marshall; Carie Corner; Virginia Wolstenholme; Charles Kelly; Adelyn Wise; Linda Collins; Sharon Love; Martha Woodward; Amanda Salisbury; Mark R Middleton
Journal:  Br J Cancer       Date:  2016-10-06       Impact factor: 7.640

2.  The efficacy and roles of combining temozolomide with whole brain radiotherapy in protection neurocognitive function and improvement quality of life of non-small-cell lung cancer patients with brain metastases.

Authors:  Xia Deng; Zhen Zheng; Baochai Lin; Huafang Su; Hanbin Chen; Shaoran Fei; Zhenghua Fei; Lihao Zhao; Xiance Jin; Cong-Ying Xie
Journal:  BMC Cancer       Date:  2017-01-10       Impact factor: 4.430

3.  Effectiveness of temozolomide combined with whole brain radiotherapy for non-small cell lung cancer brain metastases.

Authors:  Ying Zhu; Lei Fu; Wang Jing; Dong Guo; Li Kong; Jinming Yu
Journal:  Thorac Cancer       Date:  2018-06-27       Impact factor: 3.500

4.  Benefit of dosimetry distribution for patients with multiple brain metastases from non-small cell lung cancer by a Cyberknife stereotactic radiosurgery (SRS) system.

Authors:  Xuyao Yu; Yuwen Wang; Zhiyong Yuan; Hui Yu; Yongchun Song; Lujun Zhao; Ping Wang
Journal:  BMC Cancer       Date:  2020-11-25       Impact factor: 4.430
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.